Drugs / GSK1292263
last change Apr 2014 re-read 2 minutes ago

GSK1292263

also known as GSK-1292263A · GSK-263A · GSK263

Small molecule targets GPR119 via activation

Developed for
type 2 diabetes mellitus · hyperlipidemia
Investigated by
GlaxoSmithKline

Trials 5 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT01101568 Apr → Jun 2010 type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00783549 Sep 2008 → Mar 2009 hyperlipidemia GlaxoSmithKline Completed No outcome recorded
Phase 23 trials
Phase 2 NCT01218204 Sep 2010 → Jun 2011 hyperlipidemia GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT01128621 Nov 2009 → Apr 2010 type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT01119846 Jun 2009 → Mar 2010 type 2 diabetes mellitus GlaxoSmithKline Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as GSK1292263 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00783549
4

NCT01218204

NCT01101568

NCT01119846

NCT01128621

Known as GSK-1292263A ChEMBL registry synonym — accepted as the source's own label CHEMBL3187503
Known as GSK-263A ChEMBL registry synonym — accepted as the source's own label CHEMBL3187503
Known as GSK263 “We therefore investigated the pharmacology of GSK1292263 (GSK263), a selective GPR119 agonist, in two randomized, placebo-controlled studies that enrolled subjects with type 2 diabetes.” PMID 24699248 Apr 2014
Action Activate “GSK1292263 (GSK263), a selective GPR119 agonist” PMID 24699248 Apr 2014
Modality Small molecule CHEMBL3187503
Route Oral “Single Doses of Orally Administered Investigational Product” NCT00783549
Target GPR119 “We therefore investigated the pharmacology of GSK1292263 (GSK263), a selective GPR119 agonist, in two randomized, placebo-controlled studies that enrolled subjects with type 2 diabetes.” PMID 24699248 Apr 2014